Uploaded via media manager.

ARC enrolls for trial testing updated booster vaccine targeting COVID-19 variants

ARC Clinical Research, the research arm for Austin Regional Clinic, is one of the select sites across the country to participate in a BioNTech COVID-19 vaccine study testing an “updated” Pfizer‐BioNTech vaccine targeting specific variants.

This study consists of two parts. One part will evaluate the safety and efficacy of the booster injection (third shot) containing multivalent vaccine (two virus strains). The second part will evaluate the safety and efficacy of a booster injection of a monovalent vaccine (one virus strain). The results of the two parts will be compared to those who were previously vaccinated with the Pfizer‐BioNTech vaccine currently approved by the Food and Drug Administration (FDA).

The trial is enrolling healthy adults between 18 to 85 years old who are currently unvaccinated for COVID-19 and have no history of a COVID-19 infection.

“As new variants emerge with unknown risk, such as the latest Omicron, we must continue to research new approaches to ensure that our vaccines can adequately protect against COVID-19,” said Dr. Amy Siegel, Internal Medicine physician at Austin Regional Clinic and Principal Investigator at ARC Clinical Research. “If evidence emerges that the existing vaccines are less effective against the variants, trials like this one will make us better prepared.”

ARC Clinical Research is the only site in Central Texas recruiting for the BioNTech trial.

Click here to learn more about how to enroll in these trials.

Tags: ARC Clinical Research

More on this Topic

ARC’s role in the Pfizer COVID-19 vaccine trial for 12-to-15-year-olds

Pfizer recently announced their COVID-19 vaccine trial of children 12 to 15 years old has shown 100 percent efficacy to date. Drs. Anas Daghestani and Manish Naik explain ARC’s role and the import of this finding in recent interviews.

Texas, including Austin, is leading the way in COVID-19 research

Texas has emerged as a leading site for COVID-19 research, both in the search for a vaccine and for treatments for active cases. ARC Clinical research, part of this trend, has been running a COVID-19 vaccine clinical trial since early August.

ARC COVID-19 vaccine trial to continue on schedule

In response to announcements of the possible release of a COVID-19 vaccine as early as October 2020, ARC has said it will continue its vaccine trial. Dr. Anas Daghestani, CEO of ARC has said, “Our timeline is still the same.”

ARC Clinical Research contributes to COVID-19 Vaccine Trial

ARC Clinical Research is excited to announce its participation in a prominent COVID-19 vaccine clinical trial that will begin in early August 2020.  ARC will recruit 250 ARC patients from across Central Texas to enroll in this late phase clinical trial. If you are interested in enrolling, please request to participate at ARCclinicalresearch.com or call 512-225-5931.

ARC Teams with Austin-based ENTvantage Diagnostics Dx for New Clinical Trial

ARC’s newest clinical trial tests a device that could help curb antibiotic overuse, "one of the most urgent threats to the public’s health,” according to the Centers for Disease Control (CDC).